StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about BCAB. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Q3 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-101.15M | $-66.13M | $-28.93M | $-79.58M |
Net Income | $-96.54M | $-63.21M | $-27.46M | $-78.94M |
EPS (Diluted) | $-2.02 | $-1.33 | $-0.58 | $-2.11 |
Total Assets | $151.36M | $179.64M | $204.55M | $189.11M |
Total Liabilities | $56.66M | $55.12M | $48.13M | $46.48M |
Cash & Equivalents | $141.28M | $168.69M | $192.69M | $178.12M |
Free Cash Flow OCF − CapEx | $-74.18M | $-46.81M | $-22.70M | $-66.31M |
Shares Outstanding | 47.91M | 47.80M | 47.64M | 36.37M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.